Federated Hermes, Inc. Cassava Sciences Inc Transaction History

Federated Hermes, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $42,996 - $134,440	2,633 Added 172.43%	4,160 $174,000
Q2 2022 Aug 15, 2022	BUY	$17.22 - $38.47 $26,294 - $58,743	1,527 New	1,527 $43,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $3,134 - $10,147	-75 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $1,864 - $5,203	-58 Reduced 43.61%	75 $6,000
Q1 2021 May 13, 2021	BUY	$7.09 - $87.95 $942 - $11,697	133 New	133 $6,000

195

13.7M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.